Kiora Pharmaceuticals granted European and US patents for local ocular delivery of the KIO-100 family of compounds

News
Article

This intellectual property protects Kiora's pipeline by covering several inflammatory-related therapeutic applications, including posterior non-infectious uveitis.

A female patient in an eye doctor's office is examined. Image credit: ©InsideCreativeHouse – stock.adobe.com

In posterior non-infectious uveitis, the company's KIO-104 product demonstrated promising results in a Phase 1b clinical study demonstrating decreased retinal inflammation. Image credit: ©InsideCreativeHouse – stock.adobe.com

Kiora Pharmaceuticals Inc announced it has been granted European and US Patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules.

According to the company, this intellectual property (IP) further protects Kiora's pipeline by covering multiple small molecule analogs, delivery methods and several inflammatory-related therapeutic applications, including posterior non-infectious uveitis, thereby extending market exclusivity for approved indications in the US and Europe.1

Moreover, with patents issued, Kiora and any potential partners could more confidently move forward with the development and commercialisation of its KIO-100 family of compounds in combination with optimal delivery routes and formulations. In posterior non-infectious uveitis, the company's KIO-104 product demonstrated promising results in a Phase 1b clinical study demonstrating decreased retinal inflammation in a dose dependent fashion and significantly improved visual acuity compared to historical controls treated with steroids or Humira.

Brian Strem, PhD, president and CEO of Kiora, explained that the patents are a testament to the strength of the company’s R&D efforts and the importance of drug delivery.

“This milestone further strengthens the potential commercial position of KIO-104, as a safe and potent steroid-sparring approach,” Strem said in the news release.1 “This third generation DHODH inhibitor is a more potent molecule belonging to a validated class of FDA-approved anti-inflammatory drugs already benefitting tens of thousands of multiple sclerosis patients a year. KIO-104 could similarly provide benefit for patients in retinal inflammatory diseases like posterior non-infectious uveitis."

Left untreated, posterior non-infectious uveitis, an autoimmune disease highlighted by inflammation of the retina, choroid, vitreous, or optic nerve, can result in severe vision loss.

According to the company’s news release, Kiora's anti-inflammatory platform, which includes KIO-104, encompasses a family of small molecules that selectively and potently inhibit the enzyme DHODH. By inhibiting DHODH locally, these small molecules have the potential to significantly limit the deleterious inflammatory effects in the retina arising from autoimmune diseases.

Reference

1. Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis. News release. Kiora Pharmaceuticals. Published 23 August, 2023.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.